Wegovy backed for PBS listing

Nicholas O’Donoghue 22/12/2025

PBAC recommends “risk sharing arrangement” to fund PBS listing of Wegovy for established cardiovascular disease with obesity Pricing could be key for Novo Nordisk to get Wegovy (semaglutide) listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of patients with established cardiovascular disease (eCVD) living with obesity. The Pharmaceutical Benefits Advisory Committee (PBAC) recommended

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Wegovy backed for PBS listing

Previous Sigma climbs analyst’s ‘fair value’ ranks

Next Milestone agreement for pharmacy programs

MENU

ajp.com.au

Previous Sigma climbs analyst’s ‘fair value’ ranks

Next Milestone agreement for pharmacy programs

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.